Pomerantz Law Firm Investigates Potential Securities Fraud at Integra LifeSciences Holding Corporation
Pomerantz LLP has launched an investigation into Integra LifeSciences Holding Corporation (IART) following significant stock price declines and disappointing financial disclosures. The inquiry focuses on whether the company or its executives engaged in securities fraud or unlawful business practices regarding operational disruptions and revenue guidance. The volatility stems from two major events: a pre-announcement on October 2, 2026, where Integra cut its full-year revenue guidance by $30.5 million due to flooding at its Cincinnati facility, and the subsequent release of Q3 results on October 21, 2026. The company reported a significant revenue miss of $411.2 million against expectations and revealed an organic revenue contraction in its Tissue Reconstruction segment.